Q-omics provides the consensus-scored GRIA3 profile across patient tissues and cancer cell-line models. GRIA3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRIA3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GRIA3 RNA expression shows 13,699 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where GRIA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIA3 survival associations across molecular data types. GRIA3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIA3 RNA expression–survival associations across cancer types. High GRIA3 expression shows unfavorable associations in STAD, COAD and UVM, but favorable associations in ACC, CHOL and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRIA3 RNA expression.
This table summarizes GRIA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIA3 shows lower tumor expression in COAD, STAD, KICH, UCEC and BRCA and higher tumor expression in HNSC. The COAD box plot shows higher GRIA3 RNA expression in normal versus tumor tissue (log2 FC = −0.433, t-test p < 0.001).
This table shows molecular features associated with GRIA3 in patient tissues and cancer cell lines. In patient samples, GRIA3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
